Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01969435 · ClinicalTrials.gov registry record · Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01969435 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 50 participants.
The verdict
NCT01969435, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Phase II study is being conducted to confirm the safety and efficacy of high-dose Melphalan HCl for Injection (Propylene Glycol-Free) when included in the BEAM regimen for myeloablative conditioning in lymphoma patients undergoing ASCT
Interventions
- DRUG Cytarabine
- DRUG Carmustine
- DRUG Etoposide phosphate
- DRUG Melphalan HCl (propylene glycol-free)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-03-19 |
| Est. Completion | 2017-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01969435
The ClinicalTrials.gov registry entry for NCT01969435 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cytarabine is the first listed.
NCT01969435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01969435 about?
NCT01969435 is a clinical study titled "Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma". Phase II study is being conducted to confirm the safety and efficacy of high-dose Melphalan HCl for Injection (Propylene Glycol-Free) when included in the BEAM regimen for myeloablative conditioning in lymphoma patients undergoing ASCT
What is the current status of trial NCT01969435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2014-03-19. Estimated completion is 2017-05-31.
What interventions are being tested in trial NCT01969435?
The interventions under investigation include: Cytarabine (DRUG), Carmustine (DRUG), Etoposide phosphate (DRUG), Melphalan HCl (propylene glycol-free) (DRUG).
Who is sponsoring clinical trial NCT01969435?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.